Cannabix Technologies Provides Update Regarding COVID-19
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”), developer of marijuana breathalyzer devices for law enforcement and the workplace, reports that the Company and its staff remain operational at our labs in Vancouver, B.C. and Gainesville, Florida. The Company is closely monitoring the COVID-19 pandemic and has implemented additional measures at its lab locations to help safeguard the health of its staff while continuing to operate effectively. The Company has also begun preparations if further measures are implemented by governments in the coming days and weeks ahead. These preparations would allow company staff to continue operations remotely if needed. The Company has experienced some temporary delays in parts shipments from some suppliers during the month of February, however orders have been arriving at normal levels since early March. Furthermore, the Company is taking additional safety measures during breath testing with its devices.
In addition, Company engineers have been progressing development of its THC Breath Analyzer (“THCBA”) which incorporates microfluidic (MF) sensor technology for the detection of ∆9-tetrahydrocannabinol (“THC”) from breath. Over the course of February and March, engineers have been improving breath sample chamber design, incorporating additional sensors, improving the MF sensor design, improving battery life, enhancing circuitry and making changes to the form factor (exterior) design of the THCBA for better handling.About Cannabix Technologies Inc.Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC—the psychoactive component of marijuana that causes intoxication, using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.We seek Safe Harbor. On behalf of the Board of Directors“Rav Mlait”CEO
Cannabix Technologies Inc.For further information, contact the Company at email@example.comThe CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.